Jazz Pharmaceuticals Debt Rating Upgrade

S&P Global Ratings upgraded the issue‑level rating on Jazz Pharmaceuticals PLC’s senior secured debt from BB to BB+ on 8 September 2026 and simultaneously assigned a BB+ rating to a proposed $1.9 billion term loan of Jazz Financing Lux S.a.r.l. The recovery rating was lifted from 3 to 2, signalling an expected recovery rate of 70‑90% in the event of default. The new term loan extends its maturity to 2033, up from the prior 2028, and is described as leverage‑neutral.

The rating upgrade reflects S&P’s view that Jazz’s unsecured debt now provides a larger cushion to secured debt holders than previously assessed. S&P kept Jazz’s overall issuer credit rating at BB with a stable outlook, forecasting continued revenue growth and adjusted free operating cash flow of at least $1.5 billion per year.

Recent Financial and Operational Highlights

  • Q2 2026 Revenue: Jazz reported revenue of $1.2 billion, a 16% year‑over‑year increase, driven by broad‑based strength in its sleep, epilepsy, and oncology franchises.
  • FDA Approval: In August 2026, the company received FDA approval for Ziihera (zanidatamab) for first‑line treatment of HER2‑positive gastroesophageal adenocarcinoma.
  • Leverage: Jazz achieved a leverage ratio of 1.8× in 2025, comfortably below S&P’s reference range of 3‑4× for the rating.
  • Capital Raising: The firm issued $1.25 billion of 1.875% exchangeable senior notes due 2032, intending to use net proceeds mainly for general corporate purposes and to repurchase approximately $225 million of its own shares. This issuance followed the repayment of $1 billion of exchangeable senior notes in June 2026.

M&A Activity

In August 2026, Jazz announced the acquisition of Actio for an upfront cash consideration of $820 million plus up to $500 million in contingent milestone payments, targeting the late‑stage rare‑epilepsy asset ABS‑1230. The transaction, expected to close in the fourth quarter of 2026, will be funded through cash on hand and drawdowns on existing financing facilities.

S&P assumes Jazz will continue to spend roughly $2 billion annually on acquisitions, noting that outsized deals—such as the $7 billion purchase of Epidiolex in 2021—represent the greatest downside risk to the rating.

Capital Structure Overview

  • Secured revolving credit facility: $885 million, due 2033
  • Proposed secured term loan: $1.9 billion, due 2028
  • Senior secured notes: $1.5 billion
  • Unsecured exchangeable notes: $2.25 billion

These components together form Jazz’s current capital structure, supporting its strategic initiatives and providing flexibility for future financing needs.

---